AUVELITY had a demonstrated tolerability profile in clinical studies

Most common adverse reactions in the GEMINI 6-week study*

(≥5% and more than twice as frequently as placebo)1

Additional adverse reactions occurring in ≥2% of AUVELITY-treated patients and more frequently than in placebo-treated patients were nausea (13%); anxiety, constipation, decreased appetite, insomnia (at 4% each); arthralgia, fatigue,‡ paresthesia,§ vision blurred (at 3% each).1

Discontinuation rate at Week 61

4% with AUVELITY 0% with placebo

Tolerability areas of interest:

Mean Weight
Change2

-0.4 lbwith AUVELITY +0.9 lb with placebo

Anxiety1,3

4% with AUVELITY 1% with placebo

7 days (2-18 days) median duration (IQR)||¶

Dizziness3

5 days (1-15.5 days) median duration (IQR)||¶

Weight and Select Metabolic Parameters
Safety Population
Footnotes and Definitions
References

Most common adverse reactions in the GEMINI 6-week study*

(≥5% and more than twice as frequently as placebo)1

*The overall safety population includes all patients who received at least 1 dose of study medication.4

†Includes abnormal orgasm, erectile dysfunction, decreased libido, and anorgasmia.1

Mean change from baseline
in weight, cholesterol, and glucose at Week 65

BID=twice a day.